BioAtla IPO Presentation Deck

CAB CTLA-4: Potential for Disruption of the I/O Market Opportunity exists for a "safer" CTLA-4 inhibitor Outcomes • Traditional combination of anti-PD- 1 and anti-CTLA-4 checkpoint inhibitor led to improved outcomes Clinical Endpoint Progression Free Survival Grade 3 or 4 Adverse Events Discontinued Treatment Adverse Events Combination associated with increase in adverse events and treatment discontinuations Nivolumimab (PD-1)¹ 6.9 months 16.3% 7.7% Source: Larkin et al., New Eng: J. Med 373:23-34, 2015 X Unmet Need • A safe combo of PD-1/CTLA-4 has potential across many immunogenic tumors • Usage and dosage of ipilimumab (CTLA-4 inhibitor) highly limited due to its safety profile (average # of cycles on therapy does not exceed 4 cycles) bicatla Nivolumimab (PD-1) + Ipilimumab (CTLA-4)¹ 11.5 months 55.0% 36.4% • Ipilimumab dose in combination with Nivolumimab is 1/3 to 1/10 the monotherapy level, but still results in high toxicity BeiGene Global collaboration with BeiGene in place to maximize value 22

View entire presentation